PURPOSE: Hereditary papillary renal cell carcinoma is associated with mutations of the c-met proto-oncogene. Similar aberrations have been described at a molecular level in up to 13% of sporadic papillary renal cell carcinomas. We assessed c-met expression in papillary renal cell carcinomas and evaluated the prognostic significance of c-met expression in patients with this tumor. MATERIALS AND METHODS: We performed immunohistochemical testing to identify c-met expression in archival specimens of 55 papillary renal cell carcinomas in 51 patients. Only 1 patient reported a family history of renal malignancy. RESULTS: We identified c-met protein expression in the cytoplasm and cell membrane of 80% and 56% of these tumors, respectively. c-met expression significantly correlated with higher stage tumors (p = 0.004) but it was not associated with Fuhrman nuclear grade (p = 0.157). A trend toward a higher overall survival rate was noted in patients in whom tumors did not express c-met but this association failed to achieve statistical significance (p = 0.07). CONCLUSIONS: Our study indicates that c-met over expression may be associated with an aggressive phenotype in these tumors.
PURPOSE: Hereditary papillary renal cell carcinoma is associated with mutations of the c-met proto-oncogene. Similar aberrations have been described at a molecular level in up to 13% of sporadic papillary renal cell carcinomas. We assessed c-met expression in papillary renal cell carcinomas and evaluated the prognostic significance of c-met expression in patients with this tumor. MATERIALS AND METHODS: We performed immunohistochemical testing to identify c-met expression in archival specimens of 55 papillary renal cell carcinomas in 51 patients. Only 1 patient reported a family history of renal malignancy. RESULTS: We identified c-met protein expression in the cytoplasm and cell membrane of 80% and 56% of these tumors, respectively. c-met expression significantly correlated with higher stage tumors (p = 0.004) but it was not associated with Fuhrman nuclear grade (p = 0.157). A trend toward a higher overall survival rate was noted in patients in whom tumors did not express c-met but this association failed to achieve statistical significance (p = 0.07). CONCLUSIONS: Our study indicates that c-met over expression may be associated with an aggressive phenotype in these tumors.
Authors: Nizar M Tannir; Elizabeth Plimack; Chaan Ng; Pheroze Tamboli; Nebiyou B Bekele; Lianchun Xiao; Lisa Smith; Zita Lim; Lance Pagliaro; John Araujo; Ana Aparicio; Surena Matin; Christopher G Wood; Eric Jonasch Journal: Eur Urol Date: 2012-06-27 Impact factor: 20.096
Authors: Brendan D Looyenga; Kyle A Furge; Karl J Dykema; Julie Koeman; Pamela J Swiatek; Thomas J Giordano; Andrew B West; James H Resau; Bin T Teh; Jeffrey P MacKeigan Journal: Proc Natl Acad Sci U S A Date: 2011-01-10 Impact factor: 11.205
Authors: S Waalkes; F C Roos; H Eggers; S Schumacher; M Janssen; G Wegener; J W Thüroff; R Hofmann; M Schrader; M A Kuczyk; A J Schrader Journal: Urologe A Date: 2011-09 Impact factor: 0.639
Authors: Audrey N Schuetz; Qiqin Yin-Goen; Mahul B Amin; Carlos S Moreno; Cynthia Cohen; Christopher D Hornsby; Wen Li Yang; John A Petros; Muta M Issa; John G Pattaras; Kenneth Ogan; Fray F Marshall; Andrew N Young Journal: J Mol Diagn Date: 2005-05 Impact factor: 5.568
Authors: Jong Sun Choi; Mi-Kyung Kim; Jin Won Seo; Yoon-La Choi; Dong Hoon Kim; Yi Kyeong Chun; Young Hyeh Ko Journal: J Korean Med Sci Date: 2006-08 Impact factor: 2.153
Authors: Samantha Jane Wala; Jason Raj Karamchandani; Rola Saleeb; Andrew Evans; Qiang Ding; Rania Ibrahim; Michael Jewett; Maria Pasic; Antonio Finelli; Kenneth Pace; Evi Lianidou; George Makram Yousef Journal: Mol Oncol Date: 2015-05-14 Impact factor: 6.603
Authors: A J Schrader; S Rauer-Bruening; P J Olbert; A Hegele; J Rustemeier; N Timmesfeld; Z Varga; R Hofmann Journal: J Cancer Res Clin Oncol Date: 2008-11-21 Impact factor: 4.553